What does this research mean for the field?

Estimated oxygen variation measured by a commercial wearable device predicts early symptom exacerbation in COVID-19 patients with 80% sensitivity and 90% specificity. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 1, 2021JMIR Formative ResearchOpen Access

Early Detection of Symptom Exacerbation in Patients With SARS-CoV-2 Infection Using the Fitbit Charge 3 (DEXTERITY): Pilot Evaluation

Q: What is the clinical evidence from this study?

Study design: Observational. Population: COVID-19 (n=23). Intervention: Fitbit Charge 3 (estimated oxygen variation monitoring). Primary outcome: Composite of deaths of all causes, use of extracorporeal membrane oxygenation, use of mechanical ventilation, oxygenation, and exacerbation of COVID-19 symptoms, irrespective of readmission.

View Full Paper

Ask AI

Bookmark

Key result

Fitbit-estimated oxygen variation predicts early COVID-19 symptom exacerbation with ~80% sensitivity.

n=23

Why the study?

Early prediction of COVID-19 symptom exacerbation is important due to risk of sudden death from rapid deterioration and silent hypoxia in patients.

Does estimated oxygen variation (EOV) measured by a wearable device predict COVID-19 symptom exacerbation in patients with COVID-19?

Population

23 patients with COVID-19 diagnosed by positive SARS-CoV-2 PCR test, mean age 50.9 years, 70% female

Comparison

Estimated oxygen variation (EOV) signals vs resting heart rate (RHR) signals measured by Fitbit

Design

Pilot observational study with wearable device monitoring

Follow-up

30 days

Authors

KYKan Yamagami ANAkihiro NomuraPreventive Cardiology MKMitsuhiro KometaniKanazawa University

Discussion

Member takes

Implication

May support wearable monitoring for COVID-19 exacerbation; hypothesis-generating and needs prospective validation before practice change.

Study Design

Type

Observational (n=23)

Structured PICO

Does estimated oxygen variation (EOV) measured by a wearable device predict COVID-19 symptom exacerbation in patients with COVID-19?

Population

23 patients with PCR-confirmed COVID-19 (mean age 50.9 years, 70% female) who wore a Fitbit for 30 days to evaluate the prediction of symptom exacerbation.

Exposure

Fitbit Charge 3 worn for 30 days to measure estimated oxygen variation (EOV) and resting heart rate (RHR).

Outcome

Composite of deaths of all causes, use of extracorporeal membrane oxygenation, use of mechanical ventilation, oxygenation, and exacerbation of COVID-19 symptoms, irrespective of readmission.composite

Continuous monitoring of estimated oxygen variation using a commercial wearable device shows promise for early detection of COVID-19 symptom exacerbation.

Cite This Study

Yamagami et al. (2021) conducted an observational in COVID-19 (n=23). Fitbit Charge 3 (estimated oxygen variation monitoring) was evaluated on Composite of deaths of all causes, use of extracorporeal membrane oxygenation, use of mechanical ventilation, oxygenation, and exacerbation of COVID-19 symptoms, irrespective of readmission. Estimated oxygen variation measured by a Fitbit successfully predicted early COVID-19 symptom exacerbation with 80% sensitivity and 90% specificity.

synapsesocial.com/papers/6aae2809d20b29da5c992c11 https://doi.org/10.2196/30819

View Full Paper

Ask AI

Bookmark

Early Detection of Symptom Exacerbation in Patients With SARS-CoV-2 Infection Using the Fitbit Charge 3 (DEXTERITY): Pilot Evaluation

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Early Detection of Symptom Exacerbation in Patients With SARS-CoV-2 Infection Using the Fitbit Charge 3 (DEXTERITY): Pilot Evaluation

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider